#7321 ·
I’m not sure where else to turn, so I'll try here. Is medical staff legally allowed to film or take photos of patients without their consent or against their will?
Started by briskgull27 · · 👁 32 views · 7.5K replies
Nicholas Bailey3 said:Glad you got your status sorted out—it’s not exactly rocket science to change it later if things shift 👍
Emily Cook8 said:Hey, give us a heads-up once in a while so we actually know what's going on.
Harold Anderson3 said:Well, I'm back again after being away for about a month.
I've been working construction out on Maui.
The work is actually decent, and we managed to negotiate a pretty good hourly rate, though there's a catch—I'm not officially on the payroll. Out of our four-man crew, only one guy is actually registered with the state; the rest of us aren't.
To be honest, I think it might actually be for the best, because before you can get officially signed on, you have to pass a medical exam, and I already have a feeling that’s going to be a major hurdle for me.
It honestly feels like they won't let me work, and they won't let me live, either. I just can't sustain my life solely on medication. If I could just have a pension that allows me to live a normal life like some people do, I wouldn't dream of picking up a shovel or climbing a scaffold ever again.
Anyway, I don't want to bore everyone, but until I clear these loans—which should take another two and a half years—I am going to fight with everything I've got to keep working. And maybe even after that, too. I have no intention of settling for disability or social assistance; I am capable of working and I truly want to work, which is something I've proven many times over.
Nicholas Bailey3 said:Thanks, man—don't disappear on us again.☕
Harold Anderson3 said:Honestly, I actually asked for a permanent ban at one point—I can't even remember why anymore—yet here I am, still scrolling through everything, mostly just digging through that PDF and following this specific thread...
Nicholas Bailey3 said:Well, looks like you got completely distracted by that one guy's nonsense 🤣
This PDF is basically the whole story ☕
Morgan Lewis said:Hey everyone!
I was wondering about something, and maybe someone here can shed some light on it for me.
Basically, does anyone know if there’s actually a difference in how well the original Zyprexe works compared to the generic Olandix?
If anyone has gone through this or has any experience with it, I’d really appreciate the insight!
The US-based biotech firm Karuna Therapeutics Inc. has developed a new combination drug called KarXT. This might be the first new pharmacological approach to treating schizophrenia in over 50 years, which could offer a different option for people living with the condition.
KarXT is a combination therapy, meaning it puts two different drugs—xanomeline and trospium chloride—into one single treatment.
These drugs target receptors in the brain and body linked to the cholinergic neurotransmitter system, which plays a big role in things like learning, memory, digestion, heart rate, blood pressure, movement, and more. There are two types of cholinergic receptors: nicotinic and muscarinic. In KarXT, xanomeline activates the muscarinic receptors in the brain, while trospium chloride blocks those same receptors from being activated in the rest of the body.
Xanomeline was originally developed by the American pharmaceutical company Eli Lilly and Company to treat Alzheimer's disease. While trials showed it helped improve cognition and certain behavioral symptoms of Alzheimer's—like reducing delusions, agitation, and hallucinations—development stopped because some people had problematic side effects. Those issues were caused by the activation of muscarinic receptors throughout the body.
Karuna’s founder, Andrew Miller, predicted that combining trospium chloride with xanomeline would cut down those side effects, suggesting this new therapy could reduce psychosis in people living with schizophrenia.
And it worked.
We funded Karuna back in 2015 and 2018 to run Phase 1 and then Phase 2 trials for KarXT.
In the Phase 1 trial, KarXT appeared safe and well-tolerated, showing a 50% reduction in side effects compared to using xanomeline alone in healthy adults. Results from the Phase 2 trials in people with schizophrenia were also positive; in 2019, Karuna announced that KarXT led to a statistically significant reduction in psychotic symptoms. Now, seven years after our initial investment, the Phase 3 trial results for KarXT in schizophrenia show a treatment that can:
result in clinically and statistically significant improvements in psychotic symptoms, such as delusions and hallucinations, compared to a placebo
improve negative symptoms of schizophrenia—like lack of motivation, social withdrawal, and cognitive impairment, which current drugs often miss—and
avoid the usual problematic side effects seen with current antipsychotics, such as drowsiness, weight gain, and abnormal motor movements.
The KarXT trial is likely the first successful Phase 3 trial for a drug that doesn't directly rely on dopaminergic or serotonergic pathways in the brain in about 70 years. KarXT works in a completely new way and seems to be well-tolerated while easing schizophrenia symptoms, potentially offering a new treatment path for those with psychosis.